amikacin should be part of an empiric antibiotic regimen for the therapy of suspected sepsis in febrile , leukopenic immunocompromised hosts since it exhibits enhanced activity against the organisms most frequently encountered in this patient population .
C0002499
amikacin
C0036690
sepsis